Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e

Journal of Alzheimer's Disease : JAD
Thomas Adi Kurnia SusantoJuan Zhou


Knowledge of Alzheimer's disease (AD) manifestation in the pre-dementia stage facilitates the selection of appropriate measures for early detection and disease progression. To examine the trajectories of cognitive performance, gray matter volume (GMV), and cerebrospinal fluid (CSF) biomarkers, together with the influence of apolipoprotein E (APOE) in subjects with amyloid-β (Aβ) deposits across the pre-clinical to dementia stages of AD. 356 subjects were dichotomized into Aβ+ and Aβ- groups based on their CSF Aβ1-42 level. We derived AD-related atrophic regions (AD-ROIs) using the voxel-based morphometry approach. We characterized the trajectories of cognitive scores, GMV at AD-ROIs, and CSF biomarkers from preclinical to disease stages in Aβ+ subjects. The effect of APOE ε4 genotype on these trajectories was examined. Impairments in executive functioning/processing speed (EF/PS) and atrophy at the right supramarginal/inferior parietal gyrus were detected in cognitively normal Aβ+ subjects. Together with the APOE ε4 carrier status, these measures showed potential to identify cognitively normal elderly with abnormal CSF Aβ1-42 level in another independent cohort. Subsequently, impairment in memory, visuospatial, language, and at...Continue Reading


Jul 15, 2016·PloS One·Luise Christine LöweUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Mar 5, 2015·Journal of Alzheimer's Disease : JAD·Orestes Vicente ForlenzaAntonio Lucio Teixeira
Jan 7, 2017·Journal of Alzheimer's Disease : JAD·Linda J C van Waalwijk van DoornMarcel M Verbeek
Jan 23, 2020·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·Grant L IversonNoah D Silverberg
Mar 28, 2017·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Michael W WeinerUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jun 20, 2017·Dementia and Geriatric Cognitive Disorders Extra·Gaetano CorsoAlfonso Di Costanzo
Nov 1, 2016·Neurorehabilitation and Neural Repair·Weihong YuanShari L Wade
Nov 15, 2020·Ageing Research Reviews·Scott Ayton, Ashley I Bush

❮ Previous
Next ❯

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Related Papers

Acta Neuropathologica
Jon B ToledoAlzheimer’s Disease Neuroimaging Initiative
Frontiers in Aging Neuroscience
Shannon L RisacherAlzheimer's Disease Neuroimaging Initiative (ADNI)†
Proceedings of the National Academy of Sciences of the United States of America
Federica AgostaMaria Luisa Gorno-Tempini
© 2021 Meta ULC. All rights reserved